Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker

In a resounding display of market optimism, Novavax shares surged by an impressive 50% following the announcement of a groundbreaking multibillion-dollar partnership with esteemed French pharmaceutical giant, Sanofi. This transformative alliance marks a pivotal moment for the erstwhile beleaguered vaccine manufacturer.

Under the terms of the licensing agreement, Novavax gains the strategic advantage of dispensing its previously issued 'going concern' caution, a warning emblematic of its precarious financial standing just a year ago. This notable development underscores a newfound stability and confidence in the company's operational sustainability.

Market analysts unanimously laud the deal as a financial boon for Novavax, infusing the company with substantial capital resources.